Trial: 201902130

A PHASE II RANDOMIZED STUDY OF ADJUVANT VERSUS NEOADJUVANT MK-3475 (PEMBROLIZUMAB) FOR CLINICALLY DETECTABLE STAGE III-IV HIGH RISK MELANOMA

Phase

II

Principal Investigator

Ansstas, George

Disease Site

Melanoma, Skin

Learn more about this study at: clinicaltrials.gov